Schott technology group has planned to invest approximately €300m over the next three years to strengthen its pharmaceutical packaging business.
As part of the plan, the company will use the investment to expand its glass tubing business, a key component of pharmaceutical packaging.
Go deeper with GlobalData
The production capabilities of its European and Asian facilities will be increased to support the growing demand of the glass and polymer-based packaging products.
Schott management board chairman Dr Frank Heinricht said: “Today, we produce pharmaceutical glass tubing that is converted into approximately 25 billion pharmaceutical packages, such as vials, syringes, ampoules, or cartridges, produced by Schott and other suppliers around the world.
“Due to the strong demand for our products, we intend to further expand our leading position. We are now sending a signal that we are strengthening our presence in Asia.”
The company is set to open a new plant next year in the province of Zhejiang to support the demand of Fiolax glass tubing in the Chinese market. It is expecting to make future investments of up to eight-digit figures.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataSchott is also building a new melting tank at its pharmaceutical glass plant in Jambusar of Gujarat, India.
Overall, the company is investing more than €20m in the Indian plant, creating an additional 70 jobs.
Scheduled to become operational in early 2020, the new melting tank will also help to increase the production capacity for Fiolax tubes.
Furthermore, the production capacities of its sites at St Gallen in Switzerland and Müllheim in Germany will be increased to fulfil the growing demand of prefillable polymer syringes.
Made of cyclo-olefin copolymer, the Toppac polymer syringes made by Schott are lightweight and break-resistant.
New polymer syringe production lines have already started operating at the St Gallen plant, while a new production hall at Müllheim will be built by 2022.
Schott is also investing a three-digit million euro amount in the Müllheim plant where an administrative building and a pilot centre will be constructed.
